NO307645B1 - Anvendelse av probenecid i kombinasjon med en eksitatorisk aminosyre-antagonist for fremstilling av et farmasøytisk preparat - Google Patents

Anvendelse av probenecid i kombinasjon med en eksitatorisk aminosyre-antagonist for fremstilling av et farmasøytisk preparat

Info

Publication number
NO307645B1
NO307645B1 NO940809A NO940809A NO307645B1 NO 307645 B1 NO307645 B1 NO 307645B1 NO 940809 A NO940809 A NO 940809A NO 940809 A NO940809 A NO 940809A NO 307645 B1 NO307645 B1 NO 307645B1
Authority
NO
Norway
Prior art keywords
amino acid
probenecid
excitatory amino
combination
pharmaceutical composition
Prior art date
Application number
NO940809A
Other languages
English (en)
Norwegian (no)
Other versions
NO940809L (no
NO940809D0 (no
Inventor
Christopher Franklin Bigge
Jr Charles Price Taylor
Graham Johnson
Devin Franklin Welty
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO940809L publication Critical patent/NO940809L/no
Publication of NO940809D0 publication Critical patent/NO940809D0/no
Publication of NO307645B1 publication Critical patent/NO307645B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO940809A 1991-09-09 1994-03-08 Anvendelse av probenecid i kombinasjon med en eksitatorisk aminosyre-antagonist for fremstilling av et farmasøytisk preparat NO307645B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75640191A 1991-09-09 1991-09-09
PCT/US1992/007540 WO1993004688A1 (en) 1991-09-09 1992-09-02 Pharmaceutical preparation containing an uricosuric and an excitatory amino acid antagonist

Publications (3)

Publication Number Publication Date
NO940809L NO940809L (no) 1994-03-08
NO940809D0 NO940809D0 (no) 1994-03-08
NO307645B1 true NO307645B1 (no) 2000-05-08

Family

ID=25043303

Family Applications (1)

Application Number Title Priority Date Filing Date
NO940809A NO307645B1 (no) 1991-09-09 1994-03-08 Anvendelse av probenecid i kombinasjon med en eksitatorisk aminosyre-antagonist for fremstilling av et farmasøytisk preparat

Country Status (16)

Country Link
US (4) US5407935A (xx)
EP (1) EP0603301B1 (xx)
JP (1) JP3218038B2 (xx)
AT (1) ATE162075T1 (xx)
AU (1) AU660717B2 (xx)
CA (1) CA2115442C (xx)
DE (1) DE69224069T2 (xx)
DK (1) DK0603301T3 (xx)
ES (1) ES2113957T3 (xx)
GR (1) GR3026369T3 (xx)
MX (1) MX9205127A (xx)
NO (1) NO307645B1 (xx)
NZ (1) NZ244243A (xx)
PT (1) PT100850B (xx)
WO (1) WO1993004688A1 (xx)
ZA (1) ZA926837B (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU660717B2 (en) * 1991-09-09 1995-07-06 Warner-Lambert Company Pharmaceutical preparation containing an uricosuric and an excitatory amino acid antagonist
US5318985A (en) * 1991-12-20 1994-06-07 Merrell Dow Pharmaceuticals Inc. Potentiation of NMDA antagonists
US5854217A (en) 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
JPH07505908A (ja) * 1992-09-28 1995-06-29 マックセチーニ、マリア　ルイザ Ｎｍｄａ受容体のアロステリックモジュレーター
AU735389B2 (en) 1996-07-22 2001-07-05 Cognetix, Inc. Use of conantokins
US6277825B1 (en) 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
CA2261568A1 (en) 1996-07-22 1998-01-29 University Of Utah Research Foundation Conantokins
IL125950A0 (en) * 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
NZ508414A (en) * 1998-05-26 2003-12-19 Carlen Peter Louis Compositions and methods for alleviating impaired mental function, memory loss and reducing recovery time in anaesthetized mammals
US6399574B1 (en) 2000-03-22 2002-06-04 University Of Utah Research Foundation Use of conantokins
US7799794B2 (en) 2000-06-28 2010-09-21 Merck Sharp & Dohme Corp. Treatment for cardiovascular disease
US7276514B2 (en) * 2002-05-15 2007-10-02 Charitable Leadership Foundation - Medical Technology Acceleration Program Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof
US20080051428A1 (en) * 2002-05-15 2008-02-28 Davis Paul J Pyrroloquinoline quinone drugs and methods of use thereof
US20040152694A1 (en) * 2003-02-04 2004-08-05 Istvan Kurucz Methods and compositions for treating inflammatory disorders of the airways
EP1735057B1 (en) * 2004-03-22 2015-02-25 Apkarian Technologies LLC Method and compositions for treatment of chronic neuropathic pain
US8461223B2 (en) * 2005-04-07 2013-06-11 Aspen Aerogels, Inc. Microporous polycyclopentadiene-based aerogels
ITFI20050083A1 (it) * 2005-04-29 2006-10-30 Univ Firenze Uso dell'acido chinurenico per la prevenzione e il trattamento dello shock
US8841333B2 (en) 2005-05-09 2014-09-23 Takeda Pharmaceuticals U.S.A., Inc. Methods for treating nephrolithiasis
WO2007140293A2 (en) 2006-05-25 2007-12-06 Aspen Aerogels, Inc. Aerogel compositions with enhanced performance
EP2338492A1 (en) 2009-12-24 2011-06-29 Universidad del Pais Vasco Methods and compositions for the treatment of alzheimer
JP5978216B2 (ja) 2010-09-10 2016-08-24 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド テオフィリンとフェブキソスタットの併用療法のための方法
US10806711B2 (en) 2011-08-12 2020-10-20 University Of Cincinnati Method of treating acute decompensated heart failure with probenecid
AU2014244053B2 (en) 2013-03-13 2018-08-30 University Of Cincinnati Treatment of a diastolic cardiac dysfunction with a TRPV2 receptor agonist
US20170143681A1 (en) 2015-11-02 2017-05-25 Apkarian Technologies Llc Methods and compositions for treating pain
EP3427729A1 (en) * 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid for use in treating epileptic diseases, disorders or conditions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812458A (en) * 1986-09-16 1989-03-14 A/S Ferrosan 6,7-disubstituted-2,3-dihydroxyquinoxaline compounds, pharmaceutical compositions thereof, and their use as neuroleptics
DK146787A (da) * 1987-03-23 1988-09-24 Ferrosan Heterocykliske forbindelser, deres fremstilling og anvendelse
EP0501378B1 (en) * 1991-02-28 1995-01-11 Merrell Dow Pharmaceuticals Inc. NMDA Antagonists
AU660717B2 (en) * 1991-09-09 1995-07-06 Warner-Lambert Company Pharmaceutical preparation containing an uricosuric and an excitatory amino acid antagonist

Also Published As

Publication number Publication date
WO1993004688A1 (en) 1993-03-18
EP0603301A1 (en) 1994-06-29
JP3218038B2 (ja) 2001-10-15
US5407935A (en) 1995-04-18
EP0603301B1 (en) 1998-01-14
PT100850A (pt) 1993-10-29
US5942513A (en) 1999-08-24
DK0603301T3 (da) 1998-09-14
MX9205127A (es) 1993-07-01
NZ244243A (en) 1995-07-26
AU660717B2 (en) 1995-07-06
JPH06510544A (ja) 1994-11-24
US5627168A (en) 1997-05-06
AU2594392A (en) 1993-04-05
ATE162075T1 (de) 1998-01-15
CA2115442C (en) 2003-09-23
ES2113957T3 (es) 1998-05-16
PT100850B (pt) 1999-07-30
US5767119A (en) 1998-06-16
DE69224069D1 (de) 1998-02-19
GR3026369T3 (en) 1998-06-30
NO940809L (no) 1994-03-08
ZA926837B (en) 1994-03-08
DE69224069T2 (de) 1998-07-02
CA2115442A1 (en) 1993-03-18
NO940809D0 (no) 1994-03-08

Similar Documents

Publication Publication Date Title
NO307645B1 (no) Anvendelse av probenecid i kombinasjon med en eksitatorisk aminosyre-antagonist for fremstilling av et farmasøytisk preparat
ATE211384T1 (de) Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
DE69725293D1 (de) N-(2 oxoacetyl oder sulphonyl)-pyrrolidine/piperidine-2-carbonsäurederivate mit verbesserter multi-drug resistenz aktivität
ATE184792T1 (de) 2-bromomelatonin zur behandlung von schlafstörungen
ATE245977T1 (de) Therapeutische substituierte guanidine
ATE119520T1 (de) Derivate von hydroxaminsäure und von n- hydroxyharnstoff sowie ihre verwendung.
FI941826A (fi) Menetelmät ja koostumukset elimen hypofunktion ennaltaehkäisemiseksi ja/tai terapeuttiseksi hoitamiseksi
PT807633E (pt) Novas pirimidin-4-onas substituidas em 2,3, e fundidas com heteroarilo em (5,6)
UA41355C2 (uk) Засіб для лікування нейро-сніду
PT627221E (pt) Substancias antagonistas p para o tratamento de emese
DK599789A (da) 3,5-di-tertiaer-butyl-4-hydroxyphenyl-1,3,4-thiadazoler og -oxadiazoler samt 3,5-di-tertiaer-butyl-4-hydroxyphenyl-1,2,4-thiadazoler, -oxadiazoler og -triazoler som anti-inflammatoriske midler
PT100947A (pt) Pirrolidinonas heterociclicas, composicoes farmaceuticas contendo estes compostos e seu uso no tratamento de doencas alergicas e inflamatorias e para a inibicao da producao de factor de necrose tumoral
ES2106531T3 (es) Compuestos de dibenzoxazepina substituidos en 2, 3, 4, 5, 6, 7, 8, 9 y/o 10, composiciones farmaceuticas y metodos de uso.
ATE381327T1 (de) Cethylmyristat und cetylpalmitat zurbehandlung von ekzemen und/oder psoriasis
DE69820053D1 (de) Stör-notokord zur verminderung der symptome / behandlung von arthritis
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
DE59106201D1 (de) Dermatologische Zusammensetzungen mit einem Gehalt an cis-Urocaninsäure.
BR9812531A (pt) Combinação de componentes, preparação farmacêutica, produção desta, e, uso da combinação ou da preparação farmacêutica
ES2038216T3 (es) Procedimiento para la preparacion de 5-(3-alquil-5-t-butil-4-hidroxi-fenil)-2-amino-6h-1,3,4-tiadazinas y su empleo.
YU39396A (sh) Upotreba izolovanog prirodnog proteina gojaznosti za pripremu leka i njegova farmaceutska formulacija
DE69103773D1 (de) Derivate von hydroxaminsäure die lipoxygenase hemmen.
DE69630876D1 (de) Verwendung von penciclovir zur behandlung von menschlichem herpes virus-8
DE69429447D1 (de) Verwendung von 2-aminopurinderivaten zur behandlung und prophylaxe der menschlichen herpesvirus 7 infektionen
DE69429538D1 (de) Verwendung von 2-aminopurinderivaten zur behandlung und prophylaxe der menschlichen herpesvirus 6 infektionen
DE69201975D1 (de) Pyrimido-benzothiazinderivate zur Behandlung von Entzündung, Allergie and kardiovaskulären Erkrankung.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees